The Management Team
We have a world class leadership team guiding us in our quest to develop the best medicines for our best friends.
Be part of the Transformation in veterinary medicine
We love the pets around us – our dogs, cats, and horses we share our lives with. Many of us believe these animals are part of the family, providing us unconditional love and companionship throughout our lives. We have an opportunity for cutting edge treatment when disease and chronic conditions cross our path, but what happens when our animal companions encounter these same issues?
Treatment options for our companion animals shouldn’t be limited
Download the Corporate Presentation to learn more about our strategy, team, and programs.
Read the Recent News from KindredBio.
Looking for More?
See Our Pipeline
KindredBio has an exciting pipeline of high-value products for dogs, cats, and horses in development.
$4.00 
0.02 (0.61%)
0.02 (0.61%)
|
||||||||||||||||
KindredBio proudly supports
Rabies Free Africa
Kindred Biosciences Announces Positive Results from Pilot Field Efficacy Study of its IL-4/IL-13 SINK Molecule Being Developed for the Treatment of Atopic Dermatitis in Dogs
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (March 24, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from its pilot field efficacy study of KIND-025, a canine fusion protein targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), for the treatment of atopic dermatitis in dogs. The […]
Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction and Reports Fourth Quarter and Full Year 2019 Financial Results
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (March 16, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC (LSE: DPH) for an upfront payment of $43 million and royalties on worldwide […]
Kindred Biosciences to Announce Fourth Quarter and Year-End 2019 Financial Results
/in Frontpage, Investor, News /by Katja BuhrerCompany to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Monday, March 16, 2020. San Francisco, California (March 3, 2020) — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will release its fourth quarter and year-end 2019 financial results […]